​cfm#MP_​2583 [Accessed 1 July 2011] 49 Borgstrom F, Strom O, K

​cfm#MP_​2583 [Accessed 1 July 2011]. 49. Borgstrom F, Strom O, Kleman M et al (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955–65PubMedCrossRef 50. Kanis JA,

Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic Selleckchem MAPK inhibitor evaluation based on the MORE study. Osteoporos Int 16:15–25PubMedCrossRef 51. Haentjens P, De Groote K, Annemans L (2004) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary Selleck Vorinostat hip or knee replacement. A cost–utility analysis. Arch Orthop Trauma Surg 124:507–17PubMedCrossRef 52. Cleemput I, Neyt M, Thiry N, et al. Valeurs seuils pour le rapport coût-efficacité

en soins de santé. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d’expertise des soins de santé (KCE);2008. KCE Reports 100B (D/2008/10.273/95). 2008. 53. Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358:1474–82PubMedCrossRef 54. Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen AP26113 purchase SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064–71PubMedCrossRef 55. Kanis JA, Johnell O, Oden A et al (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14PubMedCrossRef 56. Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone

Miner Res 21:536–42PubMedCrossRef 57. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 22:2347–55PubMedCrossRef 58. Rabenda V, Hiligsmann M, Reginster J-Y (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303–15PubMedCrossRef 59. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565–73PubMedCrossRef 60. Selleck Gefitinib Borgstrom F, Kanis JA (2008) Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:885–900PubMedCrossRef 61. Adachi JD, Ioannidis G, Pickard L et al (2003) The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 14:895–904PubMedCrossRef 62. Papaioannou A, Kennedy CC, Ioannidis G et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703–14PubMedCrossRef 63.

Related posts:

1. N Engl J Med 335:1016–1021PubMedCrossRef 37 Naylor G, Davies MH
2. , 1995; Rosenberg et al , 2009; Hallmayer et al , 2011) Yet, due
3. , 2011) The study employing PCMS during adolescence also examine
4. Vertebroplasty does not play a role in further fracture preventio
5. , 2011), leading to the features of the disease (Schon and Area-G